Fundraising Fox
/Companies
Sign in

Oxalo Therapeutics

Chicago, US · Founded 2018 · Delaware corporation

Find your way into Oxalo Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

215 people can intro you to Yang

Ask Thomas Scaria to introduce you to Yang Zheng

You →Thomas · together at Realty Income Corporation →Yang

Sign up to find every way you can get introduced to Oxalo Therapeutics

  • Your email: who you already know at Oxalo Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Oxalo Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Oxalo Therapeutics is a preclinical-stage biopharmaceutical company developing therapies to treat and prevent diseases caused by hyperoxaluria and hyperoxalemia, such as recurrent calcium oxalate kidney stones. Its microbiome-based approach mimics a natural mechanism using gut microbes to remove oxalate from the body.

BiotechHealthtech

Founders & leadership

Oxalo Therapeutics was founded in 2018 by Yang Zheng and Hatim Hassan.

YZ
Yang ZhengCo-founder, Business leadZheng co-founded MicroQuin and has held business and operating roles across biotech and investment, including Chief Business Officer and Head of Business Development at Base4 Dynamics, VP of Operations at Seurat Therapeutics, and Director of Strategy and Operations at Clarix Imaging. Earlier in his career he was an associate at Moderne Ventures and an associate director at Realty Income Corporation, and he is based in Chicago.
HH
Hatim HassanCo-founder, R&D lead

Reported raises · per SEC filings

Form D private placements

$250K disclosed across 1 round · 2018

▶$250KraisedJun 2018 · 1 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yang ZhengDirector
  • Hatim HassanExecutive Officer, Director
Amount sold
$250K
Minimum investment
$1
First sale
Jun 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

KidneyThe National Kidney Foundation works to eliminate preventable kidney disease, accelerate innovation in patient care, and address structural inequities in kidney treatment and transplantation services. The organization serves patients with kidney disease and at-risk communities.
OupOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
Self DecodeSelfDecode is a consumer genomics platform that analyzes users' DNA, blood test results, and lifestyle data to generate 1,500+ personalized health reports and AI-driven recommendations on diet, supplements, and lifestyle. It sells DNA test kits and subscription access to tools including an AI health assistant (DecodyGPT) and lab analysis, serving consumers, doctors, and businesses.
FiveableFiveable provides AI-powered exam preparation for AP classes, offering practice questions with automated scoring and personalized study tools for high school students.

Companies working in the same space as Oxalo Therapeutics.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase IISTTR2022$1000K
National Institutes of Health (NIH)National Institutes of HealthPhase IISTTR2019$2M
National Science FoundationPhase ISTTR2019$225K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2018$300K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Oxalo Therapeutics do?
Oxalo Therapeutics is a preclinical-stage biopharmaceutical company developing therapies to treat and prevent diseases caused by hyperoxaluria and hyperoxalemia, such as recurrent calcium oxalate kidney stones. Its microbiome-based approach mimics a natural mechanism using gut microbes to remove oxalate from the body.
Who founded Oxalo Therapeutics?
Oxalo Therapeutics was founded by Yang Zheng, Hatim Hassan in 2018.
How much funding has Oxalo Therapeutics raised?
Oxalo Therapeutics has disclosed $250K raised across 1 round.
Where is Oxalo Therapeutics headquartered?
Oxalo Therapeutics is headquartered in Chicago, US.